SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)
Website: www.sbpgroup.com
(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
PHASE I CLINICAL TRIAL DATA FOR TQC3721 DRY POWDER INHALER, A "PDE3/4 INHIBITOR", PRESENTED AT ERS 2026

The board of directors (the "**Board**") of Sino Biopharmaceutical Limited (the "**Company**", together with its subsidiaries, the "**Group**") announces that data from two Phase I clinical studies of TQC3721 dry powder inhaler (DPI), a "PDE3/4 inhibitor" independently developed by the Group's subsidiary, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. ("**CTTQ**"), was presented at the European Respiratory Society 2026 Annual Meeting (ERS 2026).

Abstract Title: Safety and Efficacy of Inhaled TQC3721 (Dual PDE3/4 Inhibitor) Dry Powder: A Randomised, Double-Blind, Placebo-Controlled, Dose-Ranging Study in COPD Patients

Abstract number: 376

Presentation format: Poster session

This is a randomised, controlled, dose-escalation Phase I trial conducted in patients with chronic obstructive pulmonary disease (COPD), designed to evaluate its safety and efficacy. A total of 72 patients were enrolled in the study and randomised into six cohorts to receive escalating doses of TQC3721 DPI or placebo, with the dose-ranging interval spanning from 125 μg to 1.5 mg.

On Day 9 of treatment, the mean change from baseline in peak forced expiratory volume in one second (FEV1) following administration of TQC3721 DPI across the various dose groups showed a clear dose-dependent pattern: 300.0 mL in the 125 μg group, 288.9 mL in the 250 μg group, 263.0 mL in the 500 μg group, 344.0 mL in the 750 μg group, 497.0 mL in the 1000 μg group, and 410.0 mL in the 1500 μg group. The study found that TQC3721 DPI significantly improved lung function in patients with COPD and demonstrated good safety, with similar rates of adverse events across all groups, supporting its further clinical development.

Abstract Title: Late Breaking Abstract – A Randomised, Open-Label, Active-Controlled Phase I Study of the Inhaled Dual PDE3/4 Inhibitor TQC3721 Dry Powder Combined with Glycopyrronium Bromide in Patients with COPD

Abstract Number: 4853

Presentation format: Poster session

The second part of this Phase I study is a randomised, open-label, active-controlled proof-of-concept study designed to evaluate the safety and preliminary efficacy of the combination of TQC3721 DPI and glycopyrronium bromide. The study planned to enrol 40 patients with COPD, who were to receive TQC3721 DPI combined with glycopyrronium bromide at different doses and frequencies, or indacaterol/glycopyrronium bromide (IND/GLY) inhaled powder as positive control.

At the time of submission, among the 23 patients who had completed two weeks of treatment, the group receiving 1 mg of TQC3721 (twice daily) combined with 50 μg of glycopyrronium bromide (once daily) demonstrated clinically significant improvements in lung function compared with the IND/GLY group: a 203-mL improvement in trough FEV1 and a 110-mL improvement in peak FEV1 from baseline.

Enrolment and follow-up of all 40 subjects have now been completed. The study results are broadly consistent with the published data; the combination regimen of TQC3721 DPI and glycopyrronium bromide demonstrated bronchodilator effects comparable to those of the dual bronchodilator IND/GLY, with good tolerability and treatment-emergent adverse events (TEAEs) that were generally mild and manageable throughout the treatment period. These results provide strong support for the development of a fixed-dose combination formulation of TQC3721 DPI and LAMA. This fixed-dose combination is referred to as a triple-action dual bronchodilator.

TQC3721 is a novel PDE3/4 inhibitor independently developed by CTTQ, which aims to alleviate symptoms and suppress inflammation through the dual mechanism of bronchodilation and anti-inflammatory activity. For COPD, the TQC3721 nebulised suspension has demonstrated best-in-class potential in a Phase IIb study; this formulation is currently undergoing a Phase III clinical trial in China and has been included in the list of breakthrough therapies by the Centre for Drug Evaluation (CDE) of the China's National Medical Products Administration (NMPA); positive top-line data has also been obtained from the Phase II clinical trial of the dry powder inhaler formulation.

Sources:

[1] Safety and Efficacy of Inhaled TQC3721 (Dual PDE3/4 Inhibitor) Dry Powder: A Randomised, Double-Blind, Placebo-Controlled, Dose-Ranging Study in COPD Patients. L. Yang, L. He, et al. ERS 2026 (#376).

[2] Late Breaking Abstract – A Randomised, Open-Label, Active-Controlled Phase I Study of Inhaled Dual PDE3/4 Inhibitor TQC3721 Dry Powder Combined with Glycopyrronium Bromide in Patients with COPD. Z. Luo, L. He, et al. ERS 2026 (#4853).

[3] He LX, Yang L, Xiao ZK, et al. Effects of a Novel Dual Phosphodiesterase 3 and 4 Inhibitor TQC3721 in Patients with COPD in China (PACER-II): A Phase 2, Multicentre, Randomised, Double-Anonymised, Placebo-Controlled Trial. Chest. 2026;169(6):1536–1550. doi:10.1016/j.chest.2025.12.055

[4] Lancet. 28 April 2018:391(10131):1706–1717.

[5] Ensifentrine Plus a Long-Acting Muscarinic Antagonist in COPD: A Trifunctional Dual Bronchodilation Perspective. Drugs. September 2025;85(9):1099–1107.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 7 September 2026

As at the date of this announcement, the Board of the Company comprises five executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y and Mr. Tse Hsin and six independent non-executive directors, namely Mr. Lu Zhengfei, Ms. Lu Hong, Mr. Zhang Lu Fu, Dr. Li Kwok Tung Donald, Dr. Chen Lieping and Dr. Lu Bai.